^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Oropharyngeal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/08/2021
Excerpt:
PRINCIPLES OF SYSTEMIC THERAPY FOR NON-NASOPHARYNGEAL CANCERS (Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary sinus, Occult Primary)...Useful in Certain Circumstances...Cetuximab/pembrolizumab
